Click here for Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
The Department of Health and Social Care recommends Prevenar 13 for particular groups:
The pneumococcal vaccine programme for babies has been in place since 2006. Prevenar 13 (PCV13) replaced Prevenar (PCV7) in 2010.1
It has been estimated that in the first 11 years of the pneumococcal vaccine programme almost 40,000 cases of Invasive Pneumococcal Disease (IPD) have been prevented within the first 11 years of the pneumococcal conjugate vaccine programme.1
The Prevenar 13 vaccine is part of the childhood immunisation programme and should be administered according to the UK schedule.2
Infants who receive a first dose of Prevenar 13 should complete the vaccination course with Prevenar 13.3,4
Prevenar 13 can be co-administered with other routine paediatric vaccines administered as part of the UK national immunisation programme.2,3
Prevenar 13 is also recommended for children from their first birthday up until their second birthday who have an unknown or incomplete vaccination history.5
In addition to the childhood immunisation programme, The Green Book recommends Prevenar 13 for:6
Children aged 2 to under 10 years of age who are partially immunised or unimmunised against pneumococcal disease.
Children aged 2 to under 10 years of age who are severely immunocompromised*
Children aged 10 years and onwards and adults who are severely immunocompromised*
*Examples of severely immunocompromised include bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO).6
The Green Book refers Healthcare professionals to The British HIV Association (BHIVA) guidance for guidance on the vaccination of adults living with HIV.7
The British HIV Association (BHIVA) guidance recommends all adults who are HIV positive should receive a single dose of Prevenar 13, irrespective of CD4 cell count and antiretroviral therapy (ART).8
The Green Book outlines that infants living with HIV should receive Prevenar 13 as part of the routine childhood immunisation programme. Children living with HIV aged 2 to 10 years of age who are unimmunised or partially immunised against pneumococcal disease should receive a single dose of Prevenar 13.6
For an in-depth pneumococcal immunisation schedule for individuals in clinical risk groups please visit chapter 25 of the Green Book.
For the childhood immunisation schedule, stock comes from ImmForm.
For clinical risk groups outlined in chapter 25 of the Green Book, ImmForm should not be used. Prevenar 13 should be ordered directly from Alliance Healthcare (ImmForm stock is reserved for the infant national immunisation programme).
For more information or supply enquiries contact our Pfizer Vaccines team on: 0800 089 4033 or email [email protected]
Book your appointment below
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020